Background: The cytochalasin B-induced membrane vesicles (CIMVs) are suggested to be used as a vehicle for the delivery of therapeutics. However, the angiogenic activity and therapeutic potential of human mesenchymal stem cells (MSCs) derived CIMVs (CIMVs-MSCs) remains unknown.
The potential of Cytochalasin B-induced membrane vesicles (CIMVs) as a vector for drug delivery has been demonstrated [11] . We have previously shown that CIMVs have size similar to that of the natural EVs [12] . CIMVs also retain the biological activity of parental cells and are able to stimulate capillary tube formation in vitro and vasculogenesis in vivo [12] . These properties of CIMVs led to our interest in the evaluation of the biological activity of MSCs derived CIMVs (CIMVs-MSCs) as this might provide a potential tool for cell-free therapy.
The objectives of this study were to determine the morphology, molecular content and angiogenic activity of human CIMVs-MSCs as well as describe the membrane receptor transferring and biological activity of human CIMVs-MSCs.
Materials and methods

MSCs isolation and characterization
Human sample collection was approved by the local Ethical Committee of Kazan Signed informed consent was obtained from each donor. To obtain cell suspension the adipose tissue was cut into small pieces and treated with 0.2% collagenase II (Dia-M, Russia) in a shaker-incubator at 37 °C, 120 rpm for one hour. Cell suspension was pelleted (400g for 5 min), washed once in PBS (PanEco, Russia) and re-suspended in 4 DMEM (PanEco, Russia) supplemented with 10% fetal bovine serum (Gibco, UK) and 2mM L-glutamine (PanEco, Russia). MSCs were maintained at 37°С, 5% CO 2 with culture medium replaced every three days.
MSCs were differentiated into three directions: adipogenic, chondrogenic and osteogenic. Adipogenic, chondrogenic and osteogenic differentiation was confirmed by detection of lipid droplets (Oil Red dye staining), glycosaminoglycans and mucins (1% alcian blue staining) and calcium deposits (5% AgNO 3 staining), respectively [13] .
The immune phenotype of isolated cells was analyzed by staining with monoclonal antibodies CD90-PE/Cy5 (328112; BioLegend, USA), CD90-Brilliant Violet 421 (328122; BioLegend, USA); CD44-APC/Cy7 (103028; BioLegend, USA), CD29-APC (2115040; Sony, USA), CD73-APC (51-9007649; BD bioscience, USA), CD73-PerCPCy5.5 (344014; BioLegend, USA), STRO-1-APC/Cy7 (340104; BioLegend, USA), CD45-FITC (304006; BioLegend, USA). Expression of CD markers were analyzed by flow cytometry using BD FACS Aria III (BD bioscience, USA).
CIMVs production
CIMVs were prepared as described previously [12] . Briefly, MSCs were washed twice with PBS, and maintained in DMEM supplemented with 10 µg/ml of Cytochalasin B (Sigma-Aldrich, USA) for 30 min (37°C, 5% CO 2 ). Cell suspension was vortexed vigorously for 30 sec and pelleted (100 g for 10 min). The supernatant was collected and subject to two subsequent centrifugation steps (100g for 20 min and 2000g for 25 min). The pellet from last step, containing CIMVs-MSC, was washed once in PBS (2000g for 25 min).
Characterization of the CIMVs
Scanning electron microscopy (SEM). CIMVs were fixed (10% formalin for 15 min) and dehydrated using graded alcohol series and dried at 37°C. Prior to imaging, samples were coated with gold/palladium in a Quorum T150ES sputter coater (Quorum Technologies Ltd, United Kingdom). Slides were analyzed using Merlin field emission scanning electron microscope (CarlZeiss, Germany). For the size analysis, three independent batches of CIMVs were produced and used to generate at least six electron microscope images for each batch. Data collected was used to determine the CIMVs size.
Proteome analysis.
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CIMVs-MSCs and MSCs were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 25 mM Tris (pH 7.4)) and separated using gel polyacrylamide gel electrophoresis [14] . Gels were fixed overnight (20% ethanol and 10% acetic acid), strips were cut (1.5x1.5 mm), dehydrated using 100% acetonitrile for 20 min and dried at the room temperature. Gel fragments were rehydrated (200 mM ammonium bicarbonate, 100% acetonitrile, dH2O), placed in sequencing grademodified trypsin (Promega, USA) and incubated overnight at 37 °C. The cleaved peptides were extracted from the gel pieces using extraction buffer (0.5% trifluoroacetic acid (TFA)) and incubated in an ultrasonic bath for 10 minutes, followed by adding 100% acetonitrile and 0.5% TFA. The mixture of peptides was dried at 45°C under vacuum using Concentrator plus Complete System (Eppendorf, USA). Samples were desalted using the Acclaim PepMap 100 Columns (160321, Thermo Scientific, USA) (C18, 3 µm, 100Å) for 5 min at a 5 µl/min flow rate.
Liquid chromatography mass spectrometry analysis (LC-MS / MS) of peptide extracts was done using 3000 Nano LC nanochromatographic system (Thermo Scientific, USA) and Maxis Impact mass spectrometer with an electrospray ionization source Captive Spray (Bruker, USA). Peptides were separated by reverse phase chromatography using an Acclaim PepMap 100 NanoViper column (C18, 2µm, 100Å, 75µm × 15cm) (Thermo Scientific, USA). The tryptic peptides were eluted in a linear gradient with a mixture of solution A (4.5% acetonetrile in diH 2 O with 0.5% formic acid) and increasing percentage (from 5 to 35%) of solution B (94.5% acetonetrile with 0.5% formic acid).
Elution was done for 60 minutes at 40°C and a 300 nl/min flow rate, 1600 V of the Captive Spray source, capillary temperature 150°C, 3.0 l/min dry gas flow. The positive polarity and total spectrum measurements, data dependent acquisition (DDA) were set on Maxis Impact mass spectrometer (Bruker, USA). Peptides mass spectrum was compared to the theoretical peptide masses of all human proteins using the SWISS-PROT and NCBI databases.
Multiplex analysis
Multiplex analysis based on the xMAP Luminex technology was performed with the use 
Animals
Adult rats (Rattus norvegicus) (Pushchino, Russia) were used. All experiments were carried out in compliance with the procedure protocols approved by KFU local ethics committee (protocol #5, date 27.05.2014) according to the rules adopted by KFU and Russian Federation Laws. All experiments were repeated three times. Rats were euthanized using CO 2 in compliance with the procedure protocols approved by KFU local ethics committee (protocol #5, date 27.05.2014). Nucleus was stained using 5 μ g/ml DAPI (D1306, Invitrogen, USA).
Angiogenic activity test in vivo
Statistical analysis
Statistical analysis was done using Wilcoxon signed-rank test (R-Studio) with significance level p<0.05. Illustrations were built with "ggplot2" package (v3.1.0, 2018).
RESULTS
Isolation and characterization of human adipose-derived MSCs
Primary MSCs were isolated from human subcutaneous adipose tissue. MSCs phenotype was confirmed using antibodies against CD90, CD73, CD44, CD105 and CD45 ( Fig.1 A) . Next, differentiation potential (chondrogenic, adipogenic and osteogenic) of isolated MSCs were analyzed ( Fig.1 B) . (Fig.1 B) .
Characterization of human CIMVs-MSCs
CIMVs were successfully generated from primary human adipose MSCs (Fig.2) .
The morphology and size of the human CIMVs-MSCs were analyzed using scanning electron microscopy (SEM). CIMVs-MSCs had spherical structures and sizes ranging from 100 to 2600 nm with the majority (89.36%) having sizes between 100-1200 nm ( Fig.2 B) . Fig. 3 A) .
The unique proteins in human MSCs included nuclear (21.3%), secreted (4.6%), lysosomal (1.9%), mitochondrial (17.6%), cytoplasmic/nuclear (23.1%), cytoskeleton (1.8%), cell membrane (9.3%) and cytoplasm (20.4%) associated (Fig. 3 B) .
Peroxisome proteins were below the proteomics detection range in MSCs.
The unique proteins in CIMVs-MSCs included proteins associated with peroxisome (0.9%), lysosome (1.8%), mitochondria (6.5%), cytoplasm/nucleus (12%), cytoskeleton (20.4%), cell membrane (26%) and cytoplasm (32.4%) ( Table 1) . Levels of IL-3 and IL-13 were below the detection range in MSCs and CIMVs-MSCs.
Interestingly, levels of TGF-β, CCL7, sCD40L, IL-1b and TNF-β were higher in MSCs as compared to CIMVs-MSCs.
Immunophenotype of human CIMVs-MSCs
MSCs surface receptors play role in cell to cell contact, immunomodulation and activation of signaling in target cells [16] . Therefore, we sought to determine if CIMVs retain the surface receptors of MSCs. All parental MSCs (100%) expressed CD90, CD29, CD44 and CD73 (Fig.4 ) characteristic for the MSCs [15] . CIMVs-MSCs were positive for CD90, CD29, CD44 and CD73 (83%, 72%, 36% and 66%, respectively) (Fig.4) . Microvesicles can transfer soluble factors as well as surface receptors by the fusion of cytoplasmic membranes [17, 18] . Therefore, we sought to determine whether CIMVsMSCs could transfer the surface receptors to the recipient HEK293FT cells. HEK293FT cells were pre-stained with DiO (Invitrogen, USA) and cultured for 24 hours with DiD labeled CIMVs-MSCs (10µг/мл) (Invitrogen, USA). Expression of CD90 was selected to demonstrate receptor transfer, as it is specific for CIMVs-MSCs and absent on HEK293FT cells. Expression of CD90 was analyzed using laser scanning confocal microscope Zeiss LSM 780 (Carl Zeiss, Germany) and flow cytometry BD FACS Aria III (BD Bioscience, USA). We found that CIMVs-MSCs and HEK293FT membranes became fused and CD90 surface receptor was transferred to HEK293FT (Fig.5 D-G) .
Transfer of cell surface receptors to the recipient cell membrane by CIMVsMSCs
We determined that 99.14% of HEK293FT recipient cells acquired CD90+ immunophenotype ( Fig.5 H, I ).
CIMVs-MSCs stimulated angiogenesis in vivo
Since MSCs and CIMVs-MSCs were detected in the Matrigel matrix implants 8 days after s.c.
injection (Fig 6 D-F) . Also, newly developed blood capillaries were observed in Matrigel matrix containing MSCs and CIMVs-MSCs (Fig 6 A-C) . We found that the number of the newly developed blood vessels in control Matrigel matrix (without MSCs or CIMVs) was 0.67 ± 0.15 cap/mm 2 ( Fig.6 A, D, G). In Matrigel matrix containing MSCs, the number of newly developed blood vessels was 11.3-fold higher (7.55 ± 0.46 cap/mm 2 , p<0.01) than that in control ( Fig.6 B, E, G). Similar to MSCs, the number of the new capillaries in
Matrigel matrix containing CIMVs-MSCs was increased (5.7-fold higher (3.84 ± 0.16 cap/mm 2 , p<0.01)) than that in control (Fig.6 C, F, G). We suggest that the human CIMVs-MSCs retain the angiogenic activity of the parental MSCs. instrument based on CIMVs is only mechanistically feasible [6] . On the other hand, CIMVs-MSCs could be used to stimulate angiogenesis as they have molecular content and angiogenic activity similar to the parent MSCs. Therefore, CIMVs-MSCs could be used as a method for cell-free regenerative medicine.
Conclusions
We analyzed the molecular content, receptors expression and angiogenic potential of human MSCs and CIMVs-MSCs. Human CIMVs-MSCs has similar content, immunophenotype and angiogenic activity to that of the parental MSCs. CIMVs-MSCs could transfer membrane receptors to the surface of target cells. Therefore, we believe that human CIMVs-MSCs could be developed for cell-free therapy of degenerative diseases.
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